



ASX Announcement

Orthocell Investor Webinar Details

US Market and Operational Update

Perth, Australia; 29 January 2026: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) will conduct a webinar on Monday 2 February 2026 to provide an operational update including the status of the US roll out of Remplir™. The webinar will be presented by Orthocell Chairman, Mr John Van Der Wielen and Chief Executive Officer and Managing Director, Mr Paul Anderson.

Details of the webinar are as follows:

Investor Briefing – Webinar

When: 8.00am AWST | 11.00am AEDST Monday 2 February 2026

Register Now: https://us02web.zoom.us/webinar/register/WN_Bzb_fueGS7eOekqa6xwU1A

After registering, you will receive a confirmation email containing information about joining the webinar.

Release authorised by:

Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited

Media enquiries

Haley Chartres
H^CK Director

Investor enquiries

Shaun Duffy
VECTOR Advisors

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.